These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1134 related articles for article (PubMed ID: 17291930)
1. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930 [TBL] [Abstract][Full Text] [Related]
2. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792 [TBL] [Abstract][Full Text] [Related]
3. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958 [TBL] [Abstract][Full Text] [Related]
4. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Gurbel PA; Antonino MJ; Bliden KP; Dichiara J; Suarez TA; Singla A; Tantry US Platelets; 2008 Dec; 19(8):595-604. PubMed ID: 19012177 [TBL] [Abstract][Full Text] [Related]
5. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Gurbel PA Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887 [TBL] [Abstract][Full Text] [Related]
6. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120 [TBL] [Abstract][Full Text] [Related]
7. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Antonino MJ; Mahla E; Bliden KP; Tantry US; Gurbel PA Am J Cardiol; 2009 Jun; 103(11):1546-50. PubMed ID: 19463513 [TBL] [Abstract][Full Text] [Related]
8. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660 [TBL] [Abstract][Full Text] [Related]
9. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
12. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328 [TBL] [Abstract][Full Text] [Related]
13. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Gurbel PA; Samara WM; Bliden KP Platelets; 2004 Mar; 15(2):95-9. PubMed ID: 15154601 [TBL] [Abstract][Full Text] [Related]
14. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460 [TBL] [Abstract][Full Text] [Related]
15. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention. Tang FK; Lin LJ; Hua N; Lu H; Qi Z; Tang XZ Chin Med J (Engl); 2012 Feb; 125(4):631-8. PubMed ID: 22490487 [TBL] [Abstract][Full Text] [Related]
16. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004 [TBL] [Abstract][Full Text] [Related]
17. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149 [TBL] [Abstract][Full Text] [Related]
18. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Barrera Ramírez C; Sabaté M; Fernandez C; Hernández-Antolín R; Escaned J; Alfonso F; Macaya C J Invasive Cardiol; 2004 Apr; 16(4):169-74. PubMed ID: 15152138 [TBL] [Abstract][Full Text] [Related]
19. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Gurbel PA; Bliden KP; Hiatt BL; O'Connor CM Circulation; 2003 Jun; 107(23):2908-13. PubMed ID: 12796140 [TBL] [Abstract][Full Text] [Related]
20. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Gurbel PA; Bliden KP; Guyer K; Aggarwal N; Tantry US Thromb Res; 2007; 119(5):563-70. PubMed ID: 16806409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]